Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | WNT1 | P04628 | 4/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708722 | 0.77 | CHRNB2 (0.36) | HTR2AHTR2CWNT1GSK3BDYRK1A | |
| SCHEMBL928582 | 0.77 | HTR2A (0.36) | HTR2AHTR2CWNT1GSK3BDYRK1A | |
| SCHEMBL17687467 | 0.77 | GSK3B (0.36) | HTR2AHTR2CWNT1GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL930044 | 0.76 | HTR2A (0.36) | HTR2AHTR2CWNT1GSK3BDYRK1A | |
| SCHEMBL24024593 | 0.73 | GSK3B (0.34) | WNT1GSK3BDYRK1A | |
| SCHEMBL10183608 | 0.73 | GSK3B (0.34) | WNT1GSK3BDYRK1A | |
| SCHEMBL17788669 | 0.73 | GSK3B (0.35) | WNT1GSK3BDYRK1ACHRNB2CHRNA4 | |
| SCHEMBL13193521 | 0.73 | CPB2 (0.39) | HTR2CWNT1GSK3BDYRK1A | |
| SCHEMBL31509704 | 0.73 | MGLL (0.39) | HTR2AHTR2CWNT1GSK3BDYRK1A | |
| SCHEMBL2556005 | 0.73 | GSK3B (0.36) | HTR2AHTR2CWNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | claimed |
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | disclosed |
| EP-2424867-B1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| EP-2424867-B1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2424867-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | HTR2A 279/4885HTR2C 182/4885WNT1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.